Buy Cilostazol Online from Trusted UK Pharmacy

Cilostazol is a selective phosphodiesterase-3 inhibitor with antiplatelet and vasodilatory actions. It increases intracellular cAMP in platelets and vascular smooth muscle, thereby inhibiting platelet aggregation and promoting vasodilation; its primary clinical use is to improve walking distance in patients with intermittent claudication due to peripheral arterial disease.

Overview of Cilostazol and its drug class

Cilostazol belongs to the pharmacologic class of phosphodiesterase-3 inhibitors. By reversibly inhibiting PDE3, it elevates cyclic AMP within platelets and vascular endothelium, reducing aggregation and enhancing vasodilation. The agent is taken orally, typically as a twice-daily tablet regimen, with dosing tailored to tolerability and comorbidity.

Pharmacokinetic considerations include hepatic metabolism with active metabolites contributing to efficacy. Clinical benefit for claudication tends to emerge over weeks of therapy. Safety assessments emphasize avoidance in heart failure with reduced ejection fraction and careful monitoring in elderly patients or those with potential drug interactions.

How it compares to related substances in the same class

Among phosphodiesterase-3 inhibitors, cilostazol is notable for its oral administration and indication in claudication, whereas milrinone and related agents are used primarily in acute heart failure and are given parenterally. Milrinone provides inotropic support and vasodilation, but carries risks such as tachyarrhythmias and is not a substitute for claudication therapy.

Dipyridamole, another PDE3-inhibiting antiplatelet agent, shares vasodilatory and anti-platelet actions but serves different clinical roles, such as stroke prevention in combination with aspirin. Overall, the selection among PDE3 inhibitors depends on indication, venous or arterial symptoms, and the patient’s safety profile and comedications.

Therapeutic uses

Cilostazol is indicated to improve walking distance in patients with intermittent claudication due to peripheral arterial disease when lifestyle modification and basic measures do not provide adequate relief. It is used as an adjunct to supervised exercise programs and standard antiplatelet strategies.

In selected patients, cilostazol may be considered for symptom relief of claudication under specialist supervision. It is not a substitute for revascularization when clinically indicated, and its benefits require ongoing treatment adherence with monitoring for adverse effects.

Key differences from similar medications

The following table contrasts cilostazol with two other PDE3 inhibitors often encountered in pharmacology references. It highlights primary mechanism, typical indication, route of administration, and notable safety considerations.

In clinical practice, cilostazol remains the preferred option for oral claudication therapy when indicated, whereas milrinone and dipyridamole serve distinct cardiovascular or antiplatelet roles. Choice depends on disease indication, patient comorbidity, and risk assessment.

Safety profile summary

Common adverse effects include headache, diarrhea, dizziness, palpitations, and flushing. Serious events such as rhythm disturbances or hypotension are uncommon but clinically significant. Contraindications encompass heart failure with reduced ejection fraction and known hypersensitivity to the drug.

Monitoring focuses on blood pressure, heart rate, and signs of impaired perfusion or chest discomfort. Coadministration with strong CYP3A4 or CYP2C19 inhibitors or inducers can markedly alter cilostazol exposure, necessitating dosage adjustments or alternative therapy. Use in pregnancy requires careful risk-benefit evaluation and consultation with a specialist when applicable.